Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
International Journal of Colorectal Disease
Published in: International Journal of Colorectal Disease 10/2007

01-10-2007 | Original Article

Transforming growth factor beta 1 and metalloproteinase-9 overexpression in colorectal cancer (CC) and adenoma

Authors: Piotr Daniel, Malgorzata Wagrowska-Danilewicz, Marian Danilewicz, Olga Stasikowska, Ewa Malecka-Panas

Published in: International Journal of Colorectal Disease | Issue 10/2007

Login to get access

Abstract

Background and aims

Although the role of transforming growth factor beta (TGFbeta) 1 and metalloproteinase-9 (MMP-9) is well documented in colorectal cancer (CC), there is a little evidence supporting its role in early carcinogenesis. The aim of the study was to determine the pattern of immunohistochemical expression of TGFbeta1, MMP-9, and Ki-67 in CC and adenomatous polyps.

Patient/methods

The study group comprised 50 patients with colorectal polyps and 33 patients with CC. Endoscopically removed polyps and CC biopsies had been evaluated with histopatologic examination and immunohistochemistry. The biopsies from 30 healthy objects served as a control group. For all antibodies labeling indices (LI) had been calculated.

Results

Among 62 adenomas, 33 high-grade dysplasia (HGD) and 29 low-grade dysplasia (LGD) had been detected. Mean TGFbeta1, MMP-9, and Ki-67 LI in CC were significantly higher (p < 0.01, 0.01, and 0.01, respectively) than in HGD polyps. Mean TGFbeta1, MMP-9, and Ki-67 LI in HGD polyps were significantly higher than in LGD polyps (p < 0.01, 0.01, and 0.01, respectively). There had been no statistical difference in TGFbeta1, MMP-9, and Ki-67 LI between LGD and the control group (p > 0.05, 0.05, and 0.05, respectively). There was a positive correlation between TGFbeta1 and MMP-9 (r = 0.898), Ki-67 and MMP-9 (r = 0.938), and TGFbeta1 and Ki-67 (r = 0.913). We did not observe any correlation between TGFbeta1, MMP-9, Ki-67 LI and the clinical parameters evaluated.

Conclusion

The increased expression of TGFbeta1, MMP-9 observed in colorectal adenomas seems to be related to the grade of dysplasia. We assume that overexpression of TGFbeta1, MMP-9 represent an early event in colorectal carcinogenesis and may possibly have the prognostic value.
Literature
1.
Sehgal I, Baley AP, Thompson T (1996) Transforming growth factor β1 stimulates contrasting responses in metastatic versus primary mouse prostate cancer-derived cell lines in vitro. Cancer Res 56:3359–3365PubMed
2.
Bellone G, Carbone A, Tibaudi D, Mauri F, Ferrero I, Smirne C, Suman F, Rivetti C, Migliaretti G, Camandona M, Palestro G, Emmanueli G, Rodeck U (2001) Differential expression of transforming growth factors-β1, -β2, -β3 in human colon carcinoma. Eur J Cancer 37:224–233PubMedCrossRef
3.
4.
Matsushita M, Matsuzaki K, Date M, Watanabe T, Shibano K, Nakagawa T, Yanagitani S, Amoh Y, Takemoto H, Ogata N, Yamamoto C, Kubota Y, Seki Y, Inokuchi H, Nishizawa M, Takada H, Suwamura T, Okamura A, Inoue K (1999) Down-regulation of TGF β receptors in human colorectal cancer: implications for cancer development. Br J Cancer 80(1/2):194–205PubMedCrossRef
5.
Blobe G, Schieman W, Lodish H (2000) Role of transforming growth factor β in human disease. New Engl J Med 342:1350–1358PubMedCrossRef
6.
Ravitz MJ, Wenner CE (1997) Cyclin-dependent kinase regulation during G1 phase and cell cycle regulation by TGF β. Adv Cancer Res 71:165–207PubMedCrossRef
7.
Villanueva A, Garcia C, Paules AB, Vincente M, Megias M, Reyes G, de Villalonga P, Agell N, Lluis F, Bachs Q, Capella G (1998) Disruption of the antiproliferative TGF-β signaling pathways in human pancreatic cancer cells. Oncogene 17:1969–1978PubMedCrossRef
8.
Grady WM, Myeroff LL, Swinler SE, Rajput A, Thiagalingam S, Lutterbaugh JD, Neumann A, Brattain MG, Chang J, Kim SJ, Kinzler KW, Vogelstein B, Willson JK, Markowitz S (1999) Mutational inactivation of transforming growth factor β receptor type II in microsatellite stable colon cancers. Cancer Res 59:320–324PubMed
9.
Roberts AB, Wakefield LM (2003) The two faces of transforming growth factor β in carcinogenesis. Proc Natl Acad Sci USA 100:8621–8623PubMedCrossRef
10.
Galliher AJ, Neil JR, Schieman WP (2006) Role of transforming growth factor beta in cancer progression. Future Oncol 2(6):743–763PubMedCrossRef
11.
Pardali K, Moustakas A (2007) Actions of TGF-beta as tumor suppressor and pro-metastatic factor in human cancer. Biochim Biophys Acta 1775(1):21–62PubMed
12.
Zeng ZS, Guillem GJ (1995) Distinct pattern of matrix metalloproteinase 9 and tissue inhibitor of metalloproteinase 1 mRNA expression in human colorectal cancer and liver metastases. Br J Cancer 72:575–582PubMed
13.
Chambers AF, Matrisian LM (1997) Changing views of the role of matrix metalloproteinases in metastasis. J Natl Cancer Inst 89:1260–1270PubMedCrossRef
14.
Bernahrd EJ, Muschel RJ, Huges EN (1990) Mr 92,000 gelatinase release correlates with the metastatic phenotype in transformed rat embryo cells. Cancer Res 50:3872–3877
15.
Yamagata S, Tanaka R, Ito Y, Shimuzu S (1989) Gelatinases of murine metastatic tumor cells. Biochem Biophys Res Commun 158:228–234PubMedCrossRef
16.
Mook OR, Frederix WM, Van Noorden CJ (2004) The role of gelatinases in colorectal cancer progression and metastasis. Biochim Biophys Acta 17;1705(2):69–89
17.
Brown P, Bloxidge R, Stuart S, Gatter K, Carmichael J (1993) Association between expression of activated 72-kilodalton gelatinase and tumor spread in non-small-cell lung carcinoma. J Natl Cancer Inst 85:574–578PubMedCrossRef
18.
Brown P, Bloxidge RE, Anderson E, Howel A (1993) Expression of activated gelatinase in human invasive breast carcinoma. Clin Exp Metastasis 11:183–189PubMedCrossRef
19.
Naylor MS, Stamp GW, Davies BD, Balkwill FR (1994) Expression and activity of MMPS and their regulators in ovarian cancer. Int J Cancer 58:50–56PubMedCrossRef
20.
Satoh K, Ohtani H, Shimosegawa T, Kaizumi M, Sawai T, Toyota T (1994) Infrequent stromal expression of gelatinase A and intact basement membrane in intraductal neoplasms of the pancreas. Gastroenterology 107:1488–1495PubMed
21.
22.
Salminen E, Palmu S, Vahlberg T, Roberts PJ, Sodersttrom KO (2005) Increased proliferation activity measured by immunoreactive Ki67 is associated with survival improvement in rectal/recto-sigmoid cancer. World J Gastroenterol 11(21):3245–3249PubMed
23.
Ishida H, Sadahiro S, Suzuki T (2003) Proliferative, infiltrative and metastatic activities in colorectal tumors assessed by MIB-1 antibody. Oncol Rep 10(6):1741–1745PubMed
24.
Valera V, Yokoyama N, Walter B, Okamoto H, Suda T, Hatekeyama K (2005) Clinical significance of Ki-67 proliferation index in disease progression and prognosis of patients with resected colorectal carcinoma. Br J Surg 92:1002–1007PubMedCrossRef
25.
Baker EA, Leaper DJ (2002) Measuring gelatinase activity in colorectal cancer. Eur J Surg Oncol 28(1):24–29PubMedCrossRef
26.
D’Errico A, Garbisa S, Liotta LA, Castronovo V, Stetler-Stevenson WG, Grigioni WF (1991) Augmentation of type IV collagenase, laminin receptor, and Ki67 proliferation antigen associated with human colon, gastric, and breast carcinoma progression. Mod Path 4(2):267–280
27.
Cardillo MB, Yap E (1997) TGFbeta1 in colonic neoplasia: a genetic molecular and immunohistochemical study. J Exp Clin Cancer Res 16(3):281–288PubMed
28.
Matsushita M, Matsuzaki K, Date M, Watanabe T, Shibano K, Nakagawa T, Yanagitani S, Amoh Y, Takemoto H, Ogata N, Yamamoto C, Kubota Y, Seki T, Inokuchi H, Nishizawa M, Takada H, Sawamura T, Okamura A, Inoue K (1999) Down-regulation of TGF beta receptors in human colorectal cancer: implications for cancer development. Br J Cancer 80(1/2):194–205PubMedCrossRef
29.
Parsons SL, Watson SA, Collins HM, Griffin NR, Clarke PA, Steele RJ (1998) Gelatinase (MMP-2 and MMP-9) expression in gastrointestinal malignancy. Br J Cancer 78(11):1495–1502PubMed
30.
Tomita T, Iwata K (1996) Matrix metalloproteinases and tissue inhibitors of metalloproteinases in colonic adenomas-adenocarcinomas. Dis Colon Rectum 39:1255–1264PubMedCrossRef
31.
Sobin LH, Wittekind C (eds) (2002) TNM classification of malignant tumors, 6th edn. Wiley, New York
32.
Hamilton SR, Aaltonen LA (2000) WHO classification of tumors pathology and genetics. Tumors of the digestive system. IARC Press, Lyon
33.
Xiong B, Yuan HY, Hu MB, Zhang F, Wei ZZ, Gong LL, Yang GL (2002) Transforming growth factor beta 1 in invasion and metastasis in colorectal cancer. World J Gastroenterol 8(4):674–678PubMed
34.
Roberts AB, Wakefield LK (2003) The two faces of transforming growth factor beta in carcinogenesis. Proc Natl Acad Sci USA 100(15):8621–8630PubMedCrossRef
35.
Avery A, Paraskeva C, Hall P, Flanders KC, Sporn M, Moorghen M (1993) TGF beta expression in the human colon: differential immunostaining along crypt epithelium. Br J Cancer 68:137–139PubMed
36.
Maehara Y, Kakeji Y, Kabashima A, Emi Y, Watanabe A, Akazawa K, Baba H, Kohnoe S, Sugimachi K (1999) Role of transforming growth factor beta in invasion and metastasis in gastric carcinoma. J Clin Oncol 17:607–614PubMed
37.
Von Rahden BH, Stein HJ, Feith M, Puhringer F, Thiesen J, Siewert JR, Sarbie M (2006) Overexpression of TGF-beta1 in esophageal (Barrett’s) adenocarcinoma is associated with advanced stage of disease and poor prognosis. Mol Carcinog 45(10):786–794CrossRef
38.
Robson H, Anderson E, James RD, Shofield PF (1996) Transforming growth factor beta 1 expression in human colorectal tumors: an independent prognostic marker in a subgroup of poor prognosis patients. Br J Cancer 74(5):753–758PubMed
39.
Shimizu S, Nishikawa Y, Kuroda K, Takagi S, Kozaki K, Hyuga S, Saga S, Matsuyama M (1996) Involvement of transforming growth factor beta 1 in autocrine enhancement of gelatinase B secretion by murine metastatic colon carcinoma cells. Cancer Res 56:366–3370
40.
Berger DH, O’Mahony CA, Sheng H, Shao J, Albo D, DuBois RN, Beauchamp RD (2003) Intestinal transformation results in transforming growth factor beta-dependent alteration in tumor cell–cell matrix interaction. Surgery 133(5):568–579PubMedCrossRef
41.
Parsons SL, Watson SA, Collins HM, Griffin NR, Clarke PA, Steele RJ (1998) Gelatinase (MMP-2 and MMP-9) expression in gastrointestinal malignancy. Br J Cancer 78(11):1495–1502PubMed
42.
Zeng ZS, Cohen AM, Guillem JG (1999) Loss of basement type IV collagen is associated with increased expression of metalloproteinases 2 and 9 (MMP-2 and MMP-9) during human colorectal tumorogenesis. Carcinogenesis 20(5):749–755PubMedCrossRef
43.
Tomita T, Iwata K (1996) Matrix metalloproteinases and tissue inhibitors of metalloproteinases in colonic adenomas-adenocarcinomas. Dis Colon Rectum 39:1255–1264PubMedCrossRef
44.
Moran A, Iniesta P, Garcia Avanda C, De Juan C, Diaz-Lopez A, Sanchez-Pernaute A, Torres Aj, Diaz-Rubio E, Balibrea JL, Benito M (2005) Clinical relevance of MMP9, MMP2, TIMP-1, and TIMP-2 in colorectal cancer. Oncol Rep 13(1):115–120PubMed
45.
Saleh H, Jackson H, Khatib G, Banerjee M (1999) Correlation of bcl-2 oncoprotein immunohistochemical expression with proliferation index and histopathologic parameters in colorectal neoplasia. Pathol Oncol Res 5(4):273–279PubMedCrossRef
46.
Johnston PG, O’Brien MJ, Dervan PA, Carney DN (1989) Immunohistochemical analysis of cell kinetic parameters in colonic adenocarcinomas, adenomas, and normal mucosa. Hum Pathol 20(7):696–700PubMedCrossRef
47.
Saleh HA, Jackson H, Banerjee M (2000) Immunohiostochemical expression of bcl-2 and p53 oncoproteins: correlation with Ki-67 proliferation index and prognostic histopathologic parameters in colorectal neoplasia. Appl Immunohistochem Mol Morphol 8(3):175–182PubMedCrossRef
48.
Suzuki H, Matsumoto K, Terobe M (1992) Ki-67 antibody labeling index in colorectal carcinoma. J Clin Gastroenterol 15(4):317–320PubMedCrossRef
49.
Kyzer S, Gordon PH (1997) Determination of proliferative activity in colorectal carcinoma using monoclonal antibody Ki67. Dis Colon Rectum 40(3):322–325PubMedCrossRef
50.
Porshen R, Lohe B, Hengels KJ, Borchard F (1989) Assessment of cell proliferation in colorectal carcinomas using the monoclonal antibody Ki-67. Correlation with pathohistologic criteria and influence of irridation. Cancer 64(12):2501–2505CrossRef
51.
Oshima CT, Iriya K, Forones NM (2005) Ki-67 as a prognostic marker in colorectal cancer but not in gastric cancer. Neoplasma 52(5):420–424PubMed
52.
Jansson A, Sun XF (1997) Ki-67 expression in relation to clinicopathological variables and prognosis in colorectal adenocarcinomas. APMIS 105(9):730–734PubMedCrossRef
Metadata
Title
Transforming growth factor beta 1 and metalloproteinase-9 overexpression in colorectal cancer (CC) and adenoma
Authors
Piotr Daniel
Malgorzata Wagrowska-Danilewicz
Marian Danilewicz
Olga Stasikowska
Ewa Malecka-Panas
Publication date
01-10-2007
Publisher
Springer-Verlag
Published in
International Journal of Colorectal Disease / Issue 10/2007
Print ISSN: 0179-1958
Electronic ISSN: 1432-1262
DOI
https://doi.org/10.1007/s00384-007-0296-9

Other articles of this Issue 10/2007

International Journal of Colorectal Disease 10/2007 Go to the issue

Letter to the Editor

Post-transplant lymphoproliferative disorder presenting as acute colonic perforation

Letter to the Editor

Tailgut cysts: diagnostic challenge for both pathologists and clinicians

Original Article

Simultaneous versus staged liver resection of synchronous liver metastases from colorectal cancer

Original Article

Hsp70 response to 5-fluorouracil treatment in human colon cancer cell lines

Original Article

Ten years experience of one-stage restorative proctocolectomy for ulcerative colitis

Review

Evolution of the restorative proctocolectomy and its effects on gastrointestinal hormones